1. Introduction {#sec1}
===============

Male breast cancer represents around 1% of all breast cancers worldwide and evidence shows that it is on the rise [@bib1], [@bib2]. The rarity of male breast cancer makes conducting a prospective trial difficult but not impossible. Progress in this area has been made with collaborations between Europe and north America to launch the EORPT-BIG-NABGS prospective trial on male breast cancer. The pitfall of this paucity of male focused research and outcome data is a lack of tailored treatment regimes. This is as a result of several confounding factors, namely the low incidence, the lack of co-ordinate reporting of new cases and outcomes. The focus of recent male breast cancer research has been in understanding the importance of molecular subtyping in outcomes. Furthermore data from metastatic male breast cancer has supported the practice of utilizing female protocols to treat male patients.

Juxtaposed against the research into the hormonal and genetic interplay in male breast cancer, there is a lack of surgical outcome data for this patient group. Surgical management traditionally involves the use of a radical mastectomy to aggressively en bloc tumour resection. Despite the improvements in our understanding of the biohormonal markers of male breast cancer, little has changed or been added to the surgical armantarium. The aim of this case series is to review our centres 7 case experience of male breast cancer and to discuss the potential reasons behind a lack of surgical evolution in this disease. Finally we propose a solution to improve the change of this surgical change.

2. Methods {#sec2}
==========

A retrospective review was conducted over a 3 year period of hospital records for patients diagnosed and treated at our centre for Male breast cancer. Patient\'s notes were reviewed for demographics, histological staging, multidisciplinary team meeting outcome and treatment.

A literature review was conducted to search for all presented and published data on the surgical management of male breast cancer and comparative single centre experience. Search terms 'Male Breast Cancer AND Experience' or Male Breast Cancer AND Surgery' were used. Included articles for review were those that presented case experience of male breast cancer or discussed its surgical management. Podium presentations or posters were included. Publications were tabulated and reviewed. Articles that concerned biohormonal investigation of male breast cancer, adjuvant therapy treatment were excluded from further review or non English language were excluded.

3. Results {#sec3}
==========

3.1. Case series {#sec3.1}
----------------

Our unit reviewed a total of 7 cases over a three-year period (2006--2009) of which 4 were diagnosed as male breast cancer. The mean age of our population was 69 years with a range of 47--93 years. 2 patients had gynaecomastia prior to diagnosis. 5 patients (71%) presented with a lump in the subareolar region, whilst 2 patients (29%) presented with an ulcer on the areola that was clinically suspicious of skin cancer and referred to dermatology for formal biopsy and diagnosis. One patient\'s breast lesion was diagnosed on immunohistochemistry as a prostate metastatic secondary. 4 patients had their lesion located on the right breast, whilst 3 patients presented on the left breast. Two patients (29%) had previous malignant disease other than breast cancer prior to presentation; one had previous bladder cancer, whilst another had a previous prostate primary. [Table 1](#tbl1){ref-type="table"} highlights the outcomes of these patients.

The mean lesion size on histological examination was 15 mm. All histology (100%) showed invasive ductal carcinoma, of which only 1 patient had vascular invasion. All patients (100%) were ER receptor positive, whilst 2 patients (29%) were HER2 positive. Our histopathology department did not routinely test for progesterone receptor status, and this was not documented in the pathology records. One patient was CK7 negative, whilst the remainders were CK7 positive (86%). [Table 2](#tbl2){ref-type="table"} summarizes these histological findings.

Mortality in our group was three (43%), of which 1 refused treatment. One patient was referred to another unit due to geography. 5 patients were offered simple mastectomy with sentinel lymph node biopsy. Three patients were offered axillary node clearance for positive lymph nodes of which one declined. 1 patient received no treatments (on his request) as mentioned. 1 patient received primary hormonal treatment only (medically unfit). The chemotherapy regime in our unit was 6 cycles of Cyclophosphamide, 5 Flurouracil and Methotrexate. One patient received a cycle of epirubacin to augment his chemotherapy treatment. One patient received radiotherapy. All patients were advised of Tamoxifen tablets for 5 years, whilst the two patients with Her-2 positive histochemistry were offered Herceptin therapy.

Treatment outcomes were varied; patients were followed up for 36 months during which one patient was lost to follow-up due to desire to be referred to another unit. 3 patients had no recurrence during follow-up; two patients had local spread and one had spinal metastases. Three patients died of their disease state.

3.2. Literature review {#sec3.2}
----------------------

Literature search yielded 72 results. The results were subdivided into three cohorts. The first was conference abstracts for posters or podium presentations. Thirteen abstracts were reviewed that discussed single or multi centre experience of male breast cancer ([Table 3](#tbl3){ref-type="table"}). The largest case series in this group was 13,457 patients from the US National Cancer Data Base. The smallest groups were of 16 patients. The second group was articles that direction discussed the surgical management or published case experience of surgical techniques for male breast cancer ([Table 4](#tbl4){ref-type="table"}). Eight articles were included in this group. The largest cohort in this group reviewed the poor compliance and outcomes of lumpectomy with adjuvant therapy and partial mastectomy in 6039 male patients. The third group reviewed full text case experience publications, of which 21 were available for review ([Table 5](#tbl5){ref-type="table"}). This reflected 1390 patients in total. The largest cohort in this group was 244 patients, The mean number of patients presented in publication was 66 patients per publication. Mean age for this group was 55.5 years. Mean 5 -- year overall survival was 51.44%.

4. Discussion {#sec4}
=============

This data highlights the experience of a small oncoplastic breast units experience with locally treating male cancer over 3 years. It demonstrates the low incidence of male breast cancer presenting to loco-regional centres. These results demonstrate the need for a national and international reporting mechanism in order to collate large cohorts of data in order to improve understanding and outcomes. Our study found 100% of the patients in the case series were oestrogen-receptor (ER) positive; this significant correlation has also been widely documented [@bib1], [@bib2], alongside the paucity of triple-negative male breast cancer and on average 5% reported rate of HER2-positive cancers [@bib3]. Our study also found that 100% of the patients had invasive ductal carcinoma, consistent with widespread evidence of a low rate of in-situ disease, estimated at 11% [@bib2], [@bib4], [@bib5]. The propensity to present as an invasive ductal carcinoma with estrogen positive receptor status correlates with the findings of our literature review. ([Table 3](#tbl3){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}).

Compared to the literature our case experience is relatively small. It size correlates with other published case series from local or regional centres who treated male breast cancer. Our cohort was predominately grade 2 lesions less than 2 cm in diameter with all cases ER positive. This correlates with previously published case series. Review of the literature identifies that the majority of published experiences come from regional or national patient series ([Table 3](#tbl3){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}). Datasets presented as posters or presentations appeared to have a narrower range of patient sizes ([Table 3](#tbl3){ref-type="table"}). The largest cohort found in the literature was 13,000 patients, which had the lowest rate of surgical treatment, at 33% [@bib6]. This was the lowest rate amongst the cohorts presented at conference. The progression towards breast conserving surgery cannot be seen in these series where the rate of modified radical mastectomy remained at 96.80% in a series from 2014.

Whilst international collaborations are underway to undertake large scale prospective data collection on male breast cancer, more needs to be done to allow small centres to document their experience. This would facilitate the meta-analysis by larger academic centres. The Helsinki declaration outlines the need for research reporting in order to facilitate transparency and outcome reporting. Despite the Helsinki declaration, presenters of abstracts at international meetings are not obliged to record their data into a data registry. The online research registry is one such tool for the registration of clinical patient trials for all disciplines. The significance of small centres experience would be magnified if centres could bank their clinical experience data in a registry for further analysis. Such a platform has been trialled by Orthopaedic surgeons who used a hub and spoke system to conduct a national hip arthroplasty audit [@bib7]. Encouraging local hospitals to collate their case outcomes in a preset excel spreadsheet, the hub centre (Oxford University) could analyse each departments data individually and compare it both to other centres and the national means. This technique has also been trialled for national audit and clinical trials in reconstructive surgery (RSTN) [@bib8]. The success and robustness of regional data input into national databases for prospective analysis has also been demonstrated in the orthopaedic implant registry [@bib9] and the vascular network database [@bib10]. In both theses examples it has enabled surgical outcome data and an improvement in service delivery regionally.

The international collaboration between The EORTC [@bib11], Breast International Group (BIG), North American Breast Cancer Groups (NABCG), Borstkanker Onderzoeksgroup Nederland, Ireland Cooperative Oncology Research Group, Schweizerisches Arbeitsgemeinschaft Klin. Krebsforschung, and Swedish Association of Breast Oncologists has already facilitated a global retrospective data review of male breast cancer patients. The second phase that involves a large prospective outcomes trial is underway (EORTC trial 10,085 Male BC). This kind of large scale initiative will no doubt improve our understanding of the treatment of this pathology. The EORTC collaboration has attempted to overcome the challenges with prospective trial data collection by implementing an online data input system. Although it is difficult to quantify the number of participating institutions, potentially this system encourages a broader data capture. However this collaboration has succeeded in moving the research into male breast cancer towards the field of big data. This potentially will aggregate known information from all aspects of the disease into models that allow continual improvement and amalgamation in order to improve understanding and hypothesis generation.

The discussion of the surgical management of male breast cancer has focused on either discussing novel surgical approaches or on outcome data on radical mastectomy versus breast conserving surgery ([Table 4](#tbl4){ref-type="table"}). Our literature review identified 11 publications that discussed the surgical management of male breast cancer. Two papers present case studies of new techniques for breast conserving surgery, whilst one case study reports the use of a simple mastectomy under local anaesthetic for an obese patient with a symptomatic Aortic aneurysm. One paper discussed the benefits of fat grafting for male breast reconstruction. These cases demonstrate the paradigm shift amongst surgeons to adopt breast conserving techniques equivalent to those utilised in female breast cancer patients. One article investigates men\'s attitudes towards breast conserving surgery, particularly in their concerns over maintaining some 'aesthetic' functional breast and pectoralis shape post operatively. This is interesting as it reflects the similarities between women\'s and men\'s psychosocial reaction to breast removal and long term reconstruction [@bib12]. Little has been documented about the potential need for immediate reconstruction of male breast cancer. In one case the use of fat grafting was reported as a potential reconstructive therapy to reconstruct the male pectoral profile post mastectomy. Traditionally the male mastectomy does not leave such a large tissue defect compared to female patients. This is due to the small amount of inherent breast tissue. In cases where resection has involved some part of the chest wall, flap based reconstruction can be utilised as volume replacement. More frequently patients undergo nipple reconstruction and tattooing to provide visual balance to the chest. Recent data published in 2016 shows that for early stage male breast cancer, breast conserving surgery yields comparable cause specific survival rates to modified radical mastectomy [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]. Such data may support a paradigm shift away from larger radical procedures, as was seen in female breast cancer over two decades ago. This data is corroborated by previous work published by Cloyd and colleagues from 6039 cases. They utilised the Surveillance, Epidemiology, and End results Program (SEER database) and highlighted a change in practice during the study period, particularly towards the latter end. They demonstrated a greater proportion of patients undergoing lumpectomy over mastectomy. Nguyen presented 9 cases of male breast cancer in whom patients demanded breast conserving surgery.

Surgical options for male breast reconstruction potentially need to be low volume and provide the anatomic profile of the male chest. The deep inferior epigastric perforator flap or the transverse abdominis muscle (TRAM) flap are also potential options, particularly in patients who may excess fat tissue around the umbilicus. Due to the rates of donor site morbidity and abdominal herniation with the TRAM, the DIEP may be a more favoured option. However such flaps may be preferred for reconstruction of larger volume defects. The latissimus dorsi is also an option for reconstruction amongst female patients. It could provide a low volume local flap option for male patients, however it may compromised some degree of function in the upper extremity girdle. Techniques from chest wall reconstruction may be compromised anatomically or too aggressive for the low volume tissue deficit that remains after tumour excision.

Currently, techniques such as liposuction that are adopted for gynaecomastia are precluded as they disrupt the tissue that prevents its histopathological analysis. The peri-areolar approach with surgical removal of the remnant areola tissue remains a common technique amongst plastic surgeons for this condition. Further development of the liposuction device may allow removal of breast tissue without lysis of the cells that are required for histopathological analysis [@bib18], [@bib19], [@bib20]. This approach could provides adequate clearance and optimal aesthetic results. It may also be more conservative than a formal mastectomy, however at the moment this is merely a future direction [@bib21].

There are significant limitations to small case series. Firstly the small size precludes any meaningful statistical analysis. Secondly the disparity between data collection of case sets makes direct comparison to other centres difficult. However such weaknesses strengthen the argument for an open access free registry for recording the epidemiology and surgical outcomes of such a patient group to facilitate larger scale analysis.

5. Conclusions {#sec5}
==============

This case series and literature review has highlighted the low incidence of male breast cancer and the inherent difficulties in investigating it as a disease state. Our literature review draws attention to the number of podium presentations that focus on single centre experience of male breast cancer. Such presentations are not obligated to rec. There is currently no platform for such clinical data to record their findings in international data registries that would improve understanding. Despite the efforts of the EORTC -- BIG -- NABSG collaboration in collecting prospective data, an open access clinical case registry would enable the pooling of case experience from smaller centres for review.

Lastly it would ultimately allow a greater understanding of the surgical options employed by different centres and their overall success rates. It would enable, for the first time, a specific set of guidelines for the surgical management of male breast cancer and its reconstruction.
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###### 

Patient demographics, treatment pathway and outcomes. ANC -- Axillary Node Clearance (+ = Yes, − = No). Tx -- Treatment. F/U -- Follow Up.

  Patient         1                                          2                                                                  3                                                        4                                                            5                                                 6                                                          7
  --------------- ------------------------------------------ ------------------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------
  Presentation    Lump in sub areolar                        Hard focal lump, inner areola.                                     Red Crusted plaque over nipple and areola destruction.   Right breast lump                                            Right Breast Lump                                 Lump inch or two from Lateral left areola                  
  Gynaecomastia   No                                         Yes                                                                No                                                       No                                                           No                                                Yes                                                        No
  Treatment       Mastectomy, Chemotherapy, Tamoxifen        Nil                                                                Primary Hormonal Therapy Tx                              Offered Mastectomy + ANC - Declined Mastectomy + ANC.        Mastectomy, SLNB, LN + Ve, ANC Chemo, Tamoxifen   Mastectomy Chemotherapy Radiotherapy Herceptin Tamoxifen   Mastectomy, SNLB & LN + VE & ANC, Chemotherapy
  Follow Up       Referred on. Note CK7 Negative (Unusual)   Immunohistochemistry later revealed this was prostate Metastasis   Palliative                                               Recurrence lower pole of right nipple. Bone Metastasis T12   2 Years F/U Clear. On Tamoxifen                   2 Years. No recurrence                                     2 Years No recurrence. On Tamoxifen
  Outcome         Alive                                      Deceased                                                           Alive                                                    Alive                                                        Alive                                             Alive                                                      Alive

###### 

Histochemistry of male breast cancer lesions for patients. Gene Amp -- Gene Amplification.

  Patient             1          2          3                     4          5                                                            6          7
  ------------------- ---------- ---------- --------------------- ---------- ------------------------------------------------------------ ---------- ----------
  Age                 77         80         93                    47         63                                                           53         75
  Grade               2          2          3                     3          1                                                            2          3
  Side                Right      Left       Right                 Left       Right                                                        Left       Right
  Invasion            Yes        Yes        Yes                   Yes        Yes                                                          Yes        Yes
  Type                Ductal     Ductal     Ductal                Ductal     Ductal                                                       Ductal     Ductal
  Vascular invasion   No         No         No                    No         No                                                           No         Yes
  Size                11 mm                 11mm Deep Hard Mass   15mm       9mm                                                          22mm       22mm
  ER status           Positive   Positive   Positive              Positive   Positive                                                     Positive   Positive
  HER status          Negative   Negative   Negative              Negative   ? HER2 +ve Gene Amp --ve, immunhistochemistry stain 2 + ve   Positive   Negative

###### 

Male breast cancer experience presented at international conferences.

       Author          Year   Journal/Meeting                                                                                                                         Patients   Age     Histo                          Hormone status       5YS -- Overall survival              Surgery                                                         Mastect
  ---- --------------- ------ --------------------------------------------------------------------------------------------------------------------------------------- ---------- ------- ------------------------------ -------------------- ------------------------------------ --------------------------------------------------------------- ---------------------------------------------------
  1    Kaushik (1)     2012   Male Breast Cancer -- University Hospitals of Leicester Experience Male Breast Cancer -- University Hospitals of Leicester Experience   57         71.5    Invasive ductal carcinoma      97.60% ER +          55.60%                               41                                                              38
  2    Sedighi (2)     2014   Clinicopathologic characteristics of male breast cancer: A report of 21 cases at a radiotherapy centre in hamadan, Iran                 21         49.2    Invasive ductal                76.1% ER +           NA                                   NA                                                              NA
  3    Stevens (3)     2012   Efficacy of Aromatase Inhibitors in Male Breast Cancer n a Single Centre Experience                                                     64         NA      NA                             NA                   NA                                   NA                                                              NA
  4    Serarslan (4)   2015   Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey                               16         59.8    Infiltrative ductal ca         93.80% ER +          68%                                  62%                                                             NA
  5    Calil (5)       2014   Male breast cancer: Epidemiological study in patients attended in three academic hospitals in São Paulo                                 35         35      Invasive ductal carcinoma      88.50% ER +          78.30%                               96.80%                                                          96.90%
  6    Mueller (6)     2010   Male Breast Cancer - 25 Years Single Institution Experience                                                                             61         62      NA                             NA                   66%                                  41 patients MRM.                                                NA
  7    Ghiotto (7)     2005   Male breast cancer: our experience from 1990 to 2004                                                                                    48         60      87.50%                         75% of ER +/PR +     NA                                   97%                                                             97% - mastectomy, 1 conservative surgery
  8    Walsh (8)       2005   Adjuvant chemotherapy in stage II node positive male breast cancer.                                                                     31         61      NA                             74% ER +, 61% PR +   NA                                   100%                                                            NA
  9    Giordano (9)    2003   Male Breast Cancer: The MD Anderson experience.                                                                                         156        59                                     85% ER +, 71% PR +   86%                                  NA                                                              NA
  10   Polo (10)       2001   Long term outcome of male breast cancer. A single institution experience                                                                21         65      19pts infiltrative ductal ca   NA                   36%                                  NA                                                              NA
  11   Mohler (11)     1997   Treatment and Prognosis of Male breast cancer: the Heidelberg experience                                                                16         55      14/16 invasive ductal ca%      64% ER 82% PR        NA                                   MRM in all. 9/15 Axillary lymphonodectomy, 1 pt bilateral MBC   9/15 Axillary lymphonodectomy, 1 pt bilateral MBC
  12   Greif (12)      2013   Gender Differences in Breast Cancer: Analysis of 13,000 Male Breast Cancers From the National Cancer Data Base                          13,457     NA                                     ER 88.3%, PR 76.8    74%                                  33% partial mastectomy                                          
  13   Kwong (13)      2013   The American society of Breast surgeons                                                                                                 142        64.87                                                       94.5% ER +, 84.8 PR +, 60.5 HER2 +   73.10%                                                          76.1% mastectomy

1\. Kaushik M, Oliveira-Cunha M, Shokuhi S. Male breast cancer: a single centre experience and current evidence. Breast J. 2014; 20(6):674--5.
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8\. Walshe JM VU, Berman AW, Steinberg SM, Llpman ME, Anderson WF, Swain SM. Adjuvant Chemotherapy in stage II node positive male breast cancer. Breast Cancer Research and Treatments. 2005; 94(1).

9\. Giordano SH PG, Garcia SM, Middleton LP, Buzdar AU, Hortobagyi GN. Male breast cancer: The MD Anderson experience with adjuvant therapy. Breast Cancer Research and Treatments. 2003; 82(1):S1---S184.

10\. Polo E, Velilla C, Mayordomo J, Polo S, Filipovich E, Isla D et al. Long-term outcome of male breast cancer. A single institution experience. European Journal of Cancer.37:S170.

11\. Möhler M, Rensing K, Gutzier F, Grischke EM, Wallwiener D, Bastert G et al. Treatment and prognosis of male breast cancer: The Heidelberg experience. European Journal of Cancer.33:S156.

12\. Greif J PC, Klimberg S, Bailey L, Zuraek M, editor Gender Differences in Breast Cancer: Analysis of 13,000 Male Breast Cancers From the National Cancer Data Base. The American Society of Breast surgeons,; 2013; Pheonix.

13\. Ava Kwong WC, Oscar WK Mang, Connie HN Wong, Hong Kong Breast Cancer, Research Group SCL. Male Breast Cancer in Hong Kong -- A Population-Based Analysis of Epidemiological Characteristics, Overall, Cancer-Specific, and Disease-Free Survival in 1997--2006. The American society of Breast surgeons; Pheonix2013.

###### 

Presentations or publications discussing the surgical management of male breast cancer.

      Author          Title                                                                                                                                                                                                                        Year   Journal/Meeting                           Pts                         5YS - overall                                                                            Surgery                                                                                       WLE or lumpectomy
  --- --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ----------------------------------------- --------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------
  1   Nguyen (1)      Demand for breast-conserving surgery among male breast cancer patients                                                                                                                                                       2012   The American Society of Breast Surgeons   9                           NA                                                                                       4 patients requested breast conserving surgery.                                               
  2   Lanitis (2)     Breast conserving surgery with preservation fo the nipple areola complex as a feasible and safe approach in male breast cancer: a case report                                                                                2008   Journal of medical case reports           1                                                                                                                    Breast conserving surgery with axillary clearance, hormone therapy and radiotherapy, chemo.   
  3   Uematsu (3)     Two-step approach for the operation of male breast cancer: Report of a case at high risk for surgery                                                                                                                         1998   Kobe Journal of Medical Sciences          1                                                                                                                    Simple mastectomy under LA then 1 month later a radical mastectomy for breast cancer.         
  4   Treves (4)      the treatment of cancer, especially inoperable cancer of the male breast by ablative surgery (orchiectomy, adrenalectomy and hyphysectomy and hormone therapy (oestrogens and corticosteroids). An analysis of 42 patients   1959   Cancer                                    162                         NA                                                                                       Mastectomy, orchiectomy, adrenelectomy.                                                       
  5   Zaenger (5)     Mastectomy vs Breast Conservation for Early-Stage Male Breast Cancer: A Comparison of Oncologic Outcomes - vs breast conservation for early stage male breast cancer: A comparison of oncologic outcomes.                    2016   Oncology                                  1777                        MRM 97.3, BCT 100%                                                                       83% SM or MRM, 17% BCS, 46% receive PORT to complete tx.                                      
  6   lanitis (2)     Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report.                                                                               2008   Journal of Medical Case Reports           1 case                                                                                                                                                                                                             
  7   Cloyd (6)       Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery                                                                                                                          2013   Breast Cancer Research and Treatment      6039                        66.10%                                                                                   77.80%                                                                                        59.2% lumpectomy, 39.4% nodal positive
  8   Cloyd (7)       Outcomes of Partial mastectomy in male breast cancer patients: analysis of SEER, 1983--2009                                                                                                                                  2013   Ann Surg Oncol                            4707 + 727 (Mastect/Lump)   87.3% lumpectomy, 87.7% Mastectomy, overall survival 66 (lumpectomy)%, 70.1 mastectomy   86.80%                                                                                        13.20%
  9   Al-Kalla (8)    Breast total male breast reconstruction with fat grafting.                                                                                                                                                                   2007   Breast                                    7                           6 pts SNLB, 5 Axillary node clearance, 7 Lumpectomy/Wide Excision                        NA                                                                                            NA
      Golshan M (9)   Breast conservation for male breast carcinoma. Breast                                                                                                                                                                        2015   PRS Global Open                           1                           SNLB --ve, Mastectomy                                                                    NA                                                                                            NA

1\. Trang Nguyen MC. Demand for Breast-Conserving Surgery Among Male Breast Cancer Patients. The American Society of Breast Surgeons; Pheonix, Arizona 2012.

2\. Lanitis S, Filippakis G, Al Mufti R, Hadjiminas DJ. Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report. Journal of Medical Case Reports. 2008; 2:126.

3\. Uematsu M, Okada M, Ataka K. Two-step approach for the operation of male breast cancer: report of a case at high risk for surgery. Kobe J Med Sci. 1998; 44(4):163--8.

4\. Treves N. The treatment of cancer of the male breast, especially inoperable, by ablative surgery (orchiectomy, adrenalectomy, hypophysectomy) and the hormone therapy with estrogens and corticosteroids: an analysis of 42 patients. Acta Unio Int Contra Cancrum. 1959; 15:1169--78.

5\. Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? Clin Breast Cancer. 2015.

6\. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. Breast Cancer Res Treat. 2013; 139(1):177--82.

7\. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983--2009. Ann Surg Oncol. 2013; 20(5):1545--50.

8\. Al-Kalla T, Komorowska-Timek E. Breast total male breast reconstruction with fat grafting. Plast Reconstr Surg Glob Open. 2014; 2(11):e257.

9\. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast. 2007; 16(6):653--6.

###### 

Published full text articles discussing case experience of male breast cancer.

  Author                   Title                                                                                                             Year   Journal                                              Pts   Age     Histo                            Hormone status                5YS - overall                                                                                            Surgery                                                                                      Mastect                                        WLE or lumpectomy
  ------------------------ ----------------------------------------------------------------------------------------------------------------- ------ ---------------------------------------------------- ----- ------- -------------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------- -----------------------------------------------
  Shah P (1)               Clinicopathological study of male breast carcinoma: 24 years of experience                                        2009   Ann Saudi Med. 2009 Jul--Aug; 29 (4): 288--293.      32    NA                                                                                                                                                                                                                                                                                                                          
  Pemmaraju N (2)          Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects                   2011   Ann Oncol (2011)                                     126   61      54.7% Stage II                   97%                           NA                                                                                                       NA                                                                                           NA                                             NA
  Eldin A Elgohary S (3)   Male Breast Cancer; Experience with 6 cases                                                                       2010   2010; 8 (10) Nature and Science                      6     60      All invasive ductal carcinomas   71.40%                        NA - tx failure in 1 pt at 6 months.                                                                     5/6 Modified radical mastectomy                                                                                                             NA
  Rai B (4)                Breast cancer in males: A PGIMER experience                                                                       2005   J Cancer Res Ther - March 2005 - vol 1 -- Issue 1    30    57.13   Invasive ductal ca n = 28                                      40%                                                                                                      28                                                                                           25                                             3
  Soliman (5)              A retrospective analysis of survival and prognotstic factors of male breast cancer from a single centre           2014   BMC Cancer                                           69    58      invasive ductal                  n = 29                        46.60%                                                                                                   All underwent modified radical mastectomy with axillary lymph node dissection                NA                                             NA
  Ahmed (6)                Management and outcomes of male breast cancer in Zaria, Nigeria                                                   2012   International journal of breast cancer 2012          57    59      Invasive ductal ca 88%           57 - 100%                     22.80%                                                                                                   49                                                                                                                                          
  Yildirim (7)             Male breast cancer: 22 year experience                                                                            1998   European Journal of Surgical Oncology 24 6 548-552   121   60      87.6% invasive ductal ca.        NA                            73%                                                                                                      121                                                                                          96                                             25
  Ngoo (8)                 Male breast cancer: experience from a malaysian tertiary centre                                                   2009   Singore Med J 50 (5) 519                             6     64.5    5/6 infiltrative ductal ca       06-Jun                        NA                                                                                                       66.7% total mastectomy                                                                                                                      NA
  Masci (9)                Clinicopathological and immunohistocheimcal characteristics in male breast cancer: a retrospective case series.   2015   Oncologist Jun2015 vol 20. 6 586-592                 97    65      All invasive ductal ca           96.7% oest/prog 92.3%         68.10%                                                                                                   NA                                                                                           nA                                             NA
  Gogia (10)               Male Breast cancer: a single institute experience                                                                 2015   Indian journal of cancer                             76    59      96% Invasive ductal ca           78% ER Positive               OS rate at 3 years was 95%, 80%, 65% and 30% in Stage I, Stage II, Stage III and Stage IV respectively   52                                                                                           50                                             2
  Popovic (11)             Male Breast Cancer in the era of modern therapies: serbian since centre experience report                         2014   The Breast Journal                                   44    NA                                                                     43%                                                                                                      79%                                                                                          79%                                            
  Eryilmaz (12)            Male breast cancer: a retrospective study of 15 years                                                             2012   J BUON                                               25    67      er - 60%, PR/HER2 in 40\$/2%                                                                                                                                            72% MRM (18patients), 2 patients toilet Bilat mastectomy                                                                                    56% SNLB, 84% had SNLD
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